Navigation Links
BUSM researchers uncover cellular mechanism responsible for chronic inflammation, Type 2 diabetes
Date:12/21/2010

(Boston) Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

Barbara Nikolajczyk, PhD, an associate professor of microbiology and medicine at BUSM, is the senior author of the study, which is currently featured in an online edition of the Journal of Immunology.

T2D is a chronic inflammatory disease in which the body has high levels of glucose in the blood due to the lack of insulin or the body's inability to use insulin efficiently. The incidence of T2D continues to rise at alarming rates in both children and adults in the United States.

Previous research done in mice has shown that T cells play a critical role in the development of insulin resistance in response to a high fat diet, often leading to T2D. Additional findings indicate that T cells exhibit a pro-inflammatory response more often than an anti-inflammatory response.

Working with human T cells, the team observed that in order for T cells to exhibit the pro-inflammatory response, they required constant interaction with monocytes, indicating that monocytes play an indirect role in chronic inflammation and T2D.

While it is not known what the homeostatic balance levels are between pro-inflammatory and anti-inflammatory T cells, this study indicates the need to restore a balance in order to halt chronic inflammation and T2D.

"The true importance of our observations is the indication that altering balance among immune system cells could be a fundamentally novel treatment for T2D-associated inflammation and perhaps insulin resistance," said Nikolajczyk.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. The orange in your stocking: researchers squeezing out maximum health benefits
2. Researchers discover human immune system has emergency backup plan
3. Link between cholesterol compound and multiple sclerosis unlikely, researchers say
4. Researchers discover compound with potent effects on biological clock
5. UGA researchers develop rapid diagnostic test for common type of pneumonia
6. Freshwater sustainability challenges shared by Southwest and Southeast, researchers find
7. MGH researchers develop faster method of engineering zinc-finger nucleases
8. Researchers discover how natural drug fights inflammation
9. Researchers devise computer model for projecting severity of flu season
10. NIH awards $6.4 million to Case Western Reserve School of Medicine researchers
11. Researchers discover a way to delay Christmas tree needle loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: